Microencapsulated tumor assay: evaluation of the nude mouse model of pancreatic cancer.

AIM To establish a more stable and accurate nude mouse model of pancreatic cancer using cancer cell microencapsulation. METHODS The assay is based on microencapsulation technology, wherein human tumor cells are encapsulated in small microcapsules (approximately 420 μm in diameter) constructed of semipermeable membranes. We implemented two kinds of subcutaneous implantation models in nude mice using the injection of single tumor cells and encapsulated pancreatic tumor cells. The size of subcutaneously implanted tumors was observed on a weekly basis using two methods, and growth curves were generated from these data. The growth and metastasis of orthotopically injected single tumor cells and encapsulated pancreatic tumor cells were evaluated at four and eight weeks postimplantation by positron emission tomography-computed tomography scan and necropsy. The pancreatic tumor samples obtained from each method were then sent for pathological examination. We evaluated differences in the rates of tumor incidence and the presence of metastasis and variations in tumor volume and tumor weight in the cancer microcapsules vs single-cell suspensions. RESULTS Sequential in vitro observations of the microcapsules showed that the cancer cells in microcapsules proliferated well and formed spheroids at days 4 to 6. Further in vitro culture resulted in bursting of the membrane of the microcapsules and cells deviated outward and continued to grow in flasks. The optimum injection time was found to be 5 d after tumor encapsulation. In the subcutaneous implantation model, there were no significant differences in terms of tumor volume between the encapsulated pancreatic tumor cells and cells alone and rate of tumor incidence. There was a significant difference in the rate of successful implantation between the cancer cell microencapsulation group and the single tumor-cell suspension group (100% vs 71.43%, respectively, P = 0.0489) in the orthotropic implantation model. The former method displayed an obvious advantage in tumor mass (4th wk: 0.0461 ± 0.0399 vs 0.0313 ± 0.021, t = -0.81, P = 0.4379; 8th wk: 0.1284 ± 0.0284 vs 0.0943 ± 0.0571, t = -2.28, respectively, P = 0.0457) compared with the latter in the orthotopic implantation model. CONCLUSION Encapsulation of pancreatic tumor cells is a reliable method for establishing a pancreatic tumor animal model.

[1]  A. Watanabe,et al.  Homologous Orthotopic Implantation Models of Pancreatic Ductal Cancer in Syrian Golden Hamsters: Which Is Better for Metastasis Research—Cell Implantation or Tissue Implantation? , 2000, Pancreas.

[2]  R. Moss,et al.  Oncotargets and Therapy Dovepress Current and Emerging Therapies for the Treatment of Pancreatic Cancer , 2022 .

[3]  J. Kaspareit,et al.  An Orthotopic Model of Ductal Adenocarcinoma of the Pancreas in Severe Combined Immunodeficient Mice Representing All Steps of the Metastatic Cascade , 2001, Pancreas.

[4]  Ying Zhang,et al.  Development of an in Vitro Multicellular Tumor Spheroid Model Using Microencapsulation and Its Application in Anticancer Drug Screening and Testing , 2008, Biotechnology progress.

[5]  L. C. Schroeter CHAPTER 1 – PREPARATION AND PROPERTIES , 1966 .

[6]  D. Tarin,et al.  Effects of inoculation site and Matrigel on growth and metastasis of human breast cancer cells. , 1994, British Journal of Cancer.

[7]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis. , 1995, The American surgeon.

[8]  F. Guadagni,et al.  A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  F. Marincola,et al.  Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. , 1990, Surgery.

[10]  Y. Ikeda,et al.  Establishment and Characterization of Human Pancreatic Cancer Cell Lines in Tissue Culture and in Nude Mice , 1990, Japanese journal of cancer research : Gann.

[11]  E. Sandgren,et al.  Modeling pancreatic cancer in animals to address specific hypotheses. , 2005, Methods in molecular medicine.

[12]  A. Sun,et al.  Generation of alginate-poly-l-lysine-alginate (APA) biomicrocapsules: the relationship between the membrane strength and the reaction conditions. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[13]  B. Giovanella,et al.  The Nude Mouse in Experimental and Clinical Research , 1978 .

[14]  M. H. Tan,et al.  Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. , 1985, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[15]  S. Hirohashi,et al.  Orthotopic Transplantation Models of Pancreatic Adenocarcinoma Derived From Cell Lines and Primary Tumors and Displaying Varying Metastatic Activity , 2004, Pancreas.

[16]  T. Orfeo,et al.  Twenty-three new human tumor lines established in nude mice. , 1980, Experimental cell biology.

[17]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[18]  F. Sarkar,et al.  An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  S. Sugiura,et al.  Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells. , 2006, Cancer research.

[20]  Michael Bouvet,et al.  An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer , 2004, Clinical & Experimental Metastasis.

[21]  P. Chang,et al.  Osmotic pressure test: a simple, quantitative method to assess the mechanical stability of alginate microcapsules. , 2001, Journal of biomedical materials research.

[22]  I. Fidler,et al.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. , 1999, Neoplasia.

[23]  Gorka Orive,et al.  Microcapsules and microcarriers for in situ cell delivery. , 2010, Advanced drug delivery reviews.

[24]  David J Mooney,et al.  New materials for tissue engineering: towards greater control over the biological response. , 2008, Trends in biotechnology.

[25]  R. Shoemaker,et al.  Microencapsulated tumor assay: new short-term assay for in vivo evaluation of the effects of anticancer drugs on human tumor cell lines. , 1987, Cancer research.

[26]  F. Lim,et al.  Microencapsulated islets as bioartificial endocrine pancreas. , 1980, Science.

[27]  F. C. Macintosh,et al.  Semipermeable aqueous microcapsules. I. Preparation and properties. , 1966, Canadian journal of physiology and pharmacology.

[28]  I. Fidler,et al.  Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. , 2000, Cancer research.

[29]  H. Kleinman,et al.  Matrigel: basement membrane matrix with biological activity. , 2005, Seminars in cancer biology.